Category Archives: – Policy

How the FDA regulates compounding pharmacies

April 5, 2015- Interviewed by Steven E. Greer, MD Few people knew what a compounding pharmacy was until a meningitis outbreak traced to the

Posted in - Policy, FDA | 1 Comment

Is Vitamin-D deficiency overdiagnosed?

November 8, 2016- Interviewed by Steven E. Greer, MD We interviewed JoAnn E. Manson, MD, DrPH, Chief, Division of Preventive Medicine, Brigham

Posted in - NEJM, - Policy, CDC, Diabetes and endocrinology, FDA, Harvard, Primary care medicine | Leave a comment

The NIH has turned into a source of welfare for bloated universities

September 12, 2017- Science reports, “President Donald Trump’s administration has brought a long-simmering debate over how the U.S. government supports university research

Posted in - Opinion, Congress, NIH | 1 Comment

An emerging safety problem for TAVR patients

March 16, 2017- produced and interviewed by Steven E. Greer, MD We interviewed William O’Neill, MD, one of the first to implant a Transcatheter Aortic Valve Replacement (TAVR) valve. The products have been approved by the FDA for several years, … Continue reading

Posted in - Medical Devices, Cardiac surgery, Cardiology, FDA | Leave a comment

Changes in plastic surgery training programs

March 3, 2015- Interviewed by Steven E. Greer, MD In Part 1 of our interview with the new Chairman of Plastic Surgery at NYU, Eduardo Rodriguez,

Posted in - Policy, NYU, Plastic surgery | Leave a comment

The new CDC guidelines for prescribing opioid pain pills

June 1, 2016- Interviewed by Steven E. Greer, MD Pain pill prescriptions have quadrupled since the 1990’s as drug companies stepped up marketing and funded

Posted in - JAMA, - NEJM, - Pharma, CDC, Emergency medicine, General surgery, Oncology, Psychology Psychiatry, Rehab, Spine surgery, Sports medicine | Leave a comment

The Deans of Johns Hopkins and Miami discuss ACO’s

February 28, 2011- By Steven E Greer, MD Dean Miller of Johns Hopkins and Dean Goldschmidt of Miami discuss accountable care organizations,

Posted in - Policy, CMS, Johns Hopkins | Leave a comment

The Biggest Healthcare Stories of 2016

December 26, 2016- by Steven E. Greer, MD for The Healthcare Channel Policy changes dominated the 2016 year in healthcare news. There were few important new drug

Posted in - Biotech, - Generics, - Medical Devices, - Opinion, - Pharma, - Policy, - The Weekly Summary, CMS, FDA | Leave a comment

CDER Director Janet Woodcock on new drug safety strategies

November 16, 2010- by Steven E. Greer, MD We interviewed Dr. Janet Woodcock, long-time Director of CDER, the FDA center responsible

Posted in - Pharma, FDA | Leave a comment

The super shady methods of pricing generic drugs in America: case study- Sildenafil

May 15, 2016- by Steven E. Greer, MD The last I read, Teva and Mylan were not supposed to launch their approved generic of Viagra (sildenafil)

Posted in - Generics, - Opinion, - Pharma, CMS, Congress, FDA | Leave a comment

Insurance companies are not paying for Repatha and Praluent

March 8, 2017- Interviewed by Steven E. Greer, MD We interviewed cardiologist William O’Neill, MD about his personal need for the cholesterol-lowering, large-molecule, antibody drug from Amgen, branded as Repatha. Despite

Posted in - Biotech, - Pharma, - Policy, Cardiac surgery, Cardiology, Henry Ford, Primary care medicine | 1 Comment

The FDA pathway for biosimilar drug approvals

March 26, 2015- Interviewed by Steven E. Greer, MD

Posted in - Biotech, - Generics, FDA | Leave a comment

The MusiCorps benefit concert 2015

October 16, 2015- by Steven E. Greer, MD We interviewed the Founder of MusiCorps, Arthur Bloom, and one of the musicians in the band,

Posted in - Policy, NIH, Orthopedic surgery, Plastic surgery, Psychology Psychiatry, Trauma Surgery, VA Walter Reed | Leave a comment

The FDA’s new Breakthrough status for new drug applications

May 24, 2013- Interviewed by Steven E. Greer, MD Janet Woodcock, MD,

Posted in - Pharma, FDA | Leave a comment

Are the new PCSK9 cholesterol lowering drugs worth the high cost?

December 16, 2015- Interviewed by Steven E. Greer, MD

Posted in - Biotech, - NEJM, - Opinion, - Pharma, - Policy, Cardiology, CMS, FDA | Leave a comment

Interview with MannKind’s CEO, Al Mann, and CFO, Matt Pfeffer.

October 23, 2013- Interviewed by Steven E. Greer, MD The Healthcare Channel interviewed the CEO of MannKind, Al Mann, and the CFO, Matt Pfeffer.

Posted in - Medical Devices, Diabetes and endocrinology, FDA | Leave a comment

How to establish a face transplant team

March 3, 2015- Interviewed by Steven E. Greer, MD In Part 2 of our interview with Eduardo Rodriguez, MD, DDS, Chairman of Plastic Surgery at

Posted in - Policy, NYU, Plastic surgery | Leave a comment

Trump made a big mistake wading into the quagmire of healthcare

Is President Obama foreseeing the future here and having a laugh? May 7, 2017- Opinion by Steven E. Greer, MD I watched Face the Nation and the news coverage of Friday town hall meetings. Mick Mulvaney was

Posted in - Opinion, CMS, Congress | Leave a comment

The ACA’s THC program: A pilot program to fund residency training outside of the traditional hospital setting

September 6, 2016- Interviewed by Steven E. Greer, MD

Posted in - NEJM, - Policy, CMS, George Washington Univ | Leave a comment

Interview with the CEO of Synthetic Biologics, Jeff Riley

February 8, 2016- Interviewed by Steven E. Greer, MD

Posted in - Biotech, Gastroenterology and liver, Infectious disease, NIH | 1 Comment